Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
Featured trial
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment

A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in

  • 1324 views
  • 23 Nov, 2020
  • 1 location
Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

The main aim of this study is to investigate the possible effect of GLPG4716 on the pharmacokinetics (PK) of pirfenidone and nintedanib. Further aims are to investigate safety and tolerability

Accepts healthy volunteers
  • 0 views
  • 11 Nov, 2021
  • 1 location
A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib

The main objective of this trial is to assess single dose drug exposure of several newly developed formulation prototypes of Nintedanib compared to Ofev® following oral administration.

Accepts healthy volunteers
  • 0 views
  • 11 May, 2022
  • 1 location
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis (PROGRESSION)

-modifying therapies, pirfenidone and nintedanib, have been approved worldwide. Both drugs reduce the disease progression as measured by progressive decline in forced vital capacity (FVC), with a reduction

  • 23 views
  • 24 Mar, 2022
  • 5 locations
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD™-ON)

, InPedILD™) and for people who are between 6 and 17 years old and have fibrosing ILD. This study tests a medicine called nintedanib. Nintedanib is already used to treat different

  • 0 views
  • 12 May, 2022
  • 18 locations
Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

pirfenidone
pamrevlumab
diffusion capacity of the lung for carbon monoxide
carbon monoxide
nintedanib
  • 736 views
  • 30 Apr, 2022
  • 129 locations
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). There is a 48-week randomized treatment phase followed by an optional, open-label extension phase.

pirfenidone
pamrevlumab
diffusion capacity of the lung for carbon monoxide
carbon monoxide
nintedanib
  • 61 views
  • 05 May, 2022
  • 89 locations
Trial Of Pembrolizumab And Nintedanib (PEMBIB)

Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable. Moreover, comprehensive pre-clinical and clinical rationale sustain the hypothesis that anti-VEGF could synergize with immunotherapy for …

  • 0 views
  • 27 Jan, 2022
  • 1 location
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

The study will perform a clinical study evaluating the safety and tolerability of nintedanib when combined with standard chemotherapy (Gemcitabine + nab-Paclitaxel) for metastatic pancreatic

obstruction
measurable disease
adenocarcinoma
paclitaxel
drainage
  • 22 views
  • 27 Feb, 2022
  • 1 location
Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

The purpose of this study is to find the appropriate dose of the study drug nintedanib when combined with azacitidine and the associated side effects of the combination in older adults with AML

remission
induction therapy
cancer
human chorionic gonadotropin
hematologic malignancy
  • 2 views
  • 01 Feb, 2022
  • 1 location